{"nct_id":"NCT04676412","title":"Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) [MK-7902-007/E7080-G000-314/LEAP-007] - China Extension Study","status":"COMPLETED","status_verified_date":"2025-03","start_date":"2019-10-23","start_date_type":"ACTUAL","primary_completion_date":"2021-05-19","primary_completion_date_type":"ACTUAL","completion_date":"2024-03-29","completion_date_type":"ACTUAL","phases":["PHASE3"],"tickers":["MRK"]}